CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 268 enrolled
Drug / intervention
ISV-303 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01576952
NCT01576952Phase 3Completed
CompareCT.gov

A Randomized Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects

Sun Pharmaceutical Industries Limited·interventional·Posted Apr 13, 2012·Updated Nov 19, 2021

In Brief

A Phase 3 clinical trial evaluating ISV-303 and DuraSite Vehicle for Ocular Inflammation. Completed, enrolled 268 participants.

Detailed Summary

The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of ISV-303 compared with DuraSite Vehicle.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Inflammation
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 13, 2012
Enrollment StartJul 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.2 years ago

Interventions

ISV-303drug

Bromfenac in DuraSite

DuraSite Vehicleother

DuraSite Vehicle